secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001628280-25-029678
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vanda shareholders elect directors, ratify auditor, approve say-on-pay and equity plan amendment
--------------------------------------------------------------------------------

- Quorum of 46,577,816 shares (79.0%) represented at June 5, 2025 annual meeting.
- Directors Stephen Ray Mitchell and Tage Honoré elected with ~31.5M and ~31.3M votes for, respectively.
- Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 43.8M for, 2.3M against.
- Advisory say-on-pay approved: 28.6M for, 10.1M against, 7.7M broker non-votes.
- Amendment to 2016 Equity Incentive Plan (increase shares, eliminate term) approved: 33.0M for, 5.7M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025029678/0001628280-25-029678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828025029678/vnda-20250605.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-029678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer